Figure 1.
Figure 1. Transformation of ICSBP-/- myeloid progenitor cells by p210 Bcr/Abl. (A) Wright-Giemsa stain of parental Tot2 cells and Tot2 cells transduced with p210 Bcr/Abl retrovirus (Tot2p210 cells) (original magnification × 600). Tot2 cells were cultured in media containing GM-CSF, whereas Tot2p210 cells were cultured without GM-CSF. (B) Cell cycle analysis. Tot2 and Tot2p210 cells were analyzed for DNA content. (C) Immunoblot analysis for p210 Bcr/Abl and phosphotyrosine-containing proteins. (D) Effect of a Bcr/Abl kinase inhibitor, imatinib mesylate (STI571), on the growth and survival of Tot2 and Tot2p210 cells. Imatinib mesylate was added at indicated concentrations and viable cell number was monitored.

Transformation of ICSBP-/- myeloid progenitor cells by p210 Bcr/Abl. (A) Wright-Giemsa stain of parental Tot2 cells and Tot2 cells transduced with p210 Bcr/Abl retrovirus (Tot2p210 cells) (original magnification × 600). Tot2 cells were cultured in media containing GM-CSF, whereas Tot2p210 cells were cultured without GM-CSF. (B) Cell cycle analysis. Tot2 and Tot2p210 cells were analyzed for DNA content. (C) Immunoblot analysis for p210 Bcr/Abl and phosphotyrosine-containing proteins. (D) Effect of a Bcr/Abl kinase inhibitor, imatinib mesylate (STI571), on the growth and survival of Tot2 and Tot2p210 cells. Imatinib mesylate was added at indicated concentrations and viable cell number was monitored.

Close Modal

or Create an Account

Close Modal
Close Modal